Stryker CorporationNYSE: SYK
Health Care · Health Care Equipment
$296.89
-5.79%
Vol: 3.6M
Research Digest
Friday, May 1, 2026
Stryker reports Q1 earnings miss due to March cyberattack disruptions; maintains FY2026 guidance despite 8.5% adjusted EPS decline
Stryker's Q1 2026 revenue of $6.02B (up 2.6% YoY) and adjusted EPS of $2.60 fell short of estimates, impacted by Iran-backed cyberattack from early March to early April. Organic sales growth slowed to 2.4% while adjusted EPS declined 8.5% YoY. CEO Kevin Lobo emphasized swift recovery and team execution. Company reorganized into new Ortho Tech business unit combining orthopaedic instruments with Mako platforms. Full-year guidance reaffirmed at organic growth 8.0%-9.5% and adjusted EPS $14.90-15.10. Stock declined 3% in after-hours trading.
Previous Market Intelligence
13 daysApr 30Stryker reports Q1 earnings April 30 with analyst consensus expecting $2.98 EPS, up 5.3%Neutral▶
Stryker is releasing Q1 2026 results after market close today (April 30), with Wall Street expecting EPS of $2.98 (up 5.3% YoY) and revenues of $6.29B (up 7.3% YoY). The company acquired NICO Corporation and care.ai to strengthen minimally invasive surgery and healthcare IT capabilities. Recent cyberattack from Handala breached 200,000+ systems, creating operational challenges heading into earnings. Stock has declined 8.5% year-to-date. Strong analyst support with 20 buy and 2 hold ratings (no sells) shows market confidence despite recent cybersecurity disruption.
Apr 29Stryker earnings April 30 with Q1 2026 EPS estimate $2.98, revenue $6.29B; stock near 52-week lowNeutral▶
Stryker is set to report Q1 2026 earnings on April 30 with analyst expectations for EPS of $2.98 (up 4.9% YoY) and revenue of $6.29B (up 7.3% YoY). The company acquired Amplitude Vascular Systems for intravascular lithotripsy technology. Stock has declined 21% from 52-week high of $404.87 to current $317.67, trading near 52-week low of $319.32. Fair value estimated at $345.42 suggests potential upside. Recent Vanguard activity shows institutional confidence despite price decline.
Apr 16Stryker acquires Amplitude Vascular for intravascular lithotripsy; Q1 2026 earnings report April 30Positive▶
Stryker signed a definitive agreement on April 13 to acquire Amplitude Vascular Systems, Inc., adding next-generation intravascular lithotripsy technology to its peripheral vascular portfolio. The Amplitude acquisition addresses calcified peripheral arterial disease treatment. Despite a cybersecurity incident attributed to Iran-backed group Handala that temporarily disrupted operations, Stryker confirmed global manufacturing and critical systems have been restored. Management stated the incident will negatively affect Q1 2026 results but is not expected to impact full-year 2026 guidance (8%-9.5% organic net sales growth). Q1 2026 earnings report scheduled for April 30.
Apr 14Stryker completes cyberattack recovery; acquires Amplitude Vascular; Q1 earnings April 30Mixed▶
Completed cyberattack recovery by April 9. Acquiring Amplitude Vascular Systems for IVL technology. Citigroup Buy with $385 PT. Q1 earnings April 30.
Apr 13Stryker confirms cyberattack impact minimal; maintains 2026 guidance; Q1 earnings April 30Negative▶
Stryker disclosed Iran-linked cyberattack but confirmed no material impact on guidance (8-9.5% organic revenue growth, EPS $14.90-$15.10). Q1 2026 earnings call scheduled April 30. Dividend increased 4.8% to $0.88/share. Recent analyst downgrades: Goldman Sachs Hold, Evercore ISI target cut to $365 from $400.
Apr 10Stryker announced Q1 fiscal 2026 results on April 30 with mixed analyst sentiment.Mixed▶
Stryker will report Q1 FY2026 financial results on April 30. Declared quarterly dividend of $0.88/share (4.8% YoY increase). Q4 2025 EPS of $4.47 beat estimate. Citigroup lowered target from $420 to $385; Goldman Sachs initiated Hold rating. Stock trading at $345 with 40.49 P/E ratio.
Apr 9Stryker recovers from cyberattack; Q4 revenue up 11.4%Neutral▶
Stryker reports Q4 revenue growth of 11.4% YoY and launches SmartHospital Platform for digital healthcare. Company recovering from pro-Iranian Handala cyberattack that affected 200,000+ systems and disrupted order processing/manufacturing. Analysts at Jefferies and William Blair maintain Outperform ratings citing strong core business fundamentals.
Apr 8Evercore ISI lowers Stryker price target to $365; Q1 results April 30.Negative▶
Evercore ISI lowered Stryker target from $400 to $365 on April 6, maintaining Outperform. Citigroup also maintains Buy but lowered target to $385. Q1 FY2026 results April 30 after market close. Consensus from 32 firms shows Outperform status.
Apr 7Stryker Q1 2026 results due April 30; recovering from recent cyberattack.Mixed▶
Stryker announced financial results for Q1 fiscal 2026 will be reported on April 30, 2026 with press release at 4:05 p.m. ET and webcast at 4:30 p.m. ET. Company is recovering from recent cyberattack that disrupted operations. Spencer Stiles was appointed President and COO effective January 1, 2026. 2025 net sales reached $25.116 billion (+11.2% YoY) versus $22.595 billion in 2024. Annual Meeting of Shareholders scheduled for May 6, 2026. Investors await Q1 results insight into attack impact and long-term growth targeting $32.1 billion revenue by 2029.
Apr 6Stryker Q1 2026 earnings April 30; dividend declared $0.88/share (+4.8% YoY).Positive▶
Stryker declared $0.88 quarterly dividend, +4.8% YoY. Recovering from March cyberattack; manufacturing operations mostly restored. Q1 2026 results April 30 at 4:05pm ET. Stock at $331.54.
Apr 3Stryker fully operational three weeks after Iranian cyberattack; launches Mako RPS robotic system and SmartHospital Platform.Positive▶
Stryker recovered from a March 11 cyberattack claimed by the Iranian-linked Handala hacktivist group, which wiped approximately 80,000 devices. Despite the disruption, Q4 revenue increased 11.4% year-over-year. Stryker announced the Mako RPS (Robotic Power System) for Total Knee. The company also launched its SmartHospital Platform. Nick Mead becomes VP of Investor Relations effective May 1. Analysts maintain Buy ratings.
Apr 1Stryker Corporation announces 4.8% dividend increase to $0.88/share payable April 30 amid strong Q4 results.Neutral▶
Stryker declared a quarterly dividend of $0.88 per share, payable April 30, 2026, representing a 4.8% YoY increase. Company reported strong Q4 2025 with net sales of $7.17 billion (+11.4%) and full-year 2025 net sales of $25.12 billion (+11.2%). 2026 outlook includes organic sales growth of 8.0-9.5% and adjusted EPS of $14.90-$15.10. Stock is down 9% from all-time highs. Company navigating recovery from March cyberattack.
Mar 31Stryker recovered from cyberattack; declared $0.88 dividend and launched SmartHospital with 11.4% Q4 revenue growth.Positive▶
Stryker recovering from March cyberattack. Declared $0.88 quarterly dividend (ex-date March 31). Q4 revenue grew 11.4% YoY. Limited release of Mako RPS for Total Knee. Stock at $327.44. UBS lowered PT to $380.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ISRGINTUITIVE | $458.41 | +0.17% | +1.1% | 38.8x | 1.68 | $162.1B |
| ABTABBOTT | $89.66 | -1.25% | -11.3% | 15.0x | 0.78 | $157.8B |
| SYKSTRYKER | $296.89 | -5.79% | -5.2% | 18.8x | 0.93 | $120.7B |
| MDTMEDTRONIC | $80.38 | -0.73% | -6.2% | 13.4x | 0.76 | $104.0B |
| BSXBOSTON | $56.75 | -1.50% | -8.0% | 15.3x | 0.78 | $85.6B |
| EWEDWARDS | $84.28 | +0.93% | +2.9% | 24.8x | 0.94 | $48.1B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.